Clinical Trial Update: Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety of lenalidomide and markers for disease progression in IPSS low- or intermediate-1 risk myelodysplastic syndromes with isolated d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED